Effectiveness of live attenuated influenza vaccine and inactivated influenza vaccine in children 2-17 years of age in 2013-2014 in the United States

Vaccine

Volumn 34, Issue 1, 2016, Pages 77-82

  Caspard, Herve ^a   Gaglani, Manjusha ^b   Clipper, Lydia ^b   Belongia, Edward A ^c   McLean, Huong Q ^c   Griffin, Marie R ^d   Talbot, H Keipp ^d   Poehling, Katherine A ^e   Peters, Timothy R ^e   Veney, Naomi ^a   Ambrose, Christopher S ^a  

^a ASTRAZENECA   (United Kingdom)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c MARSHFIELD CLINIC   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

LAIV; Pediatrics; Quadrivalent live attenuated influenza vaccine

Indexed keywords

INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; INACTIVATED VACCINE; LIVE VACCINE;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA A VIRUS (H1N1); INFLUENZA B; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NONHUMAN; NOSE SMEAR; OBSERVATIONAL STUDY; OUTPATIENT CARE; PRIORITY JOURNAL; REGISTER; RESPIRATORY TRACT DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNITED STATES; VIRUS STRAIN; IMMUNOLOGY; INFLUENZA, HUMAN; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; TREATMENT OUTCOME; UNITED STATES; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 84949730119     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.11.010     Document Type: Article

References (20)

1. Grohskopf L.A., Olsen S.J., Sokolow L.Z., Bresee J.S., Cox N.J., Broder K.R., et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) - United States, 2014-2015 influenza season. MMWR Morb Mortal Wkly Rep 2014, 63:691-697.
2. Jackson M.L., Nelson J.C. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 2013, 31:2165-2168.
3. De Serres G., Skowronski D.M., Wu X.W., Ambrose C.S. The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials. Euro Surveill 2013, 18(September (37)). pii:20585.
4. Belongia E.A., Kieke B.A., Donahue J.G., Greenlee R.T., Balish A., Foust A., et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis 2009, 199:159-167.
5. Griffin M.R., Monto A.S., Belongia E.A., Treanor J.J., Chen Q., Chen J., et al. Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. PLoS ONE 2011, 6:e23085.
6. Treanor J.J., Talbot H.K., Ohmit S.E., Coleman L.A., Thompson M.G., Cheng P.Y., et al. Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. Clin Infect Dis 2012, 55:951-959.
7. Ohmit S.E., Thompson M.G., Petrie J.G., Thaker S.N., Jackson M.L., Belongia E.A., et al. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis 2014, 58:319-327.
8. McLean H.Q., Thompson M.G., Sundaram M.E., Kieke B.A., Gaglani M., Murthy K., et al. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis 2015, 211:1529-1540.
9. Orenstein W.A., Bernier R.H., Dondero T.J., Hinman A.R., Marks J.S., Bart K.J., et al. Field evaluation of vaccine efficacy. Bull World Health Organ 1985, 63:1055-1068.
10. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989, 79(March (3)):340-349.
11. Kelly H., Jacoby P., Dixon G.A., Carcione D., Williams S., Moore H.C., et al. Vaccine effectiveness against laboratory-confirmed influenza in healthy young children: a case-control study. Pediatr Infect Dis J 2011, 30:107-111.
12. Ambrose C.S., Wu X., Knuf M., Wutzler P. The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies. Vaccine 2012, 30:886-892.
13. Flannery B. Update on effectiveness of live-attenuated versus inactivated influenza vaccines in children and adolescents aged 2-18 years - US Flu VE Network. Advisory Committee on Immunization Practices (ACIP) October 2014 Meeting 2014, Available at: http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2014-10/flu-03-flannery.pdf [accessed 10.06.15].
14. Coelingh K. Update on live attenuated influenza vaccine (LAIV). ACIP February 2015 Meeting 2015, Available at: http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2015-02/flu-02-Coelingh.pdf [accessed 10.06.15].
15. Kwong J.C., Pereira J., Quach S., Pellizzari R., Dusome E., Russell M., et al. Randomized Evaluation of Live Attenuated vs. Trivalent Inactivated influenza Vaccines in Schools (RELATIVES) pilot study: preliminary results from the household surveillance sub-study 2015, Available at: http://cic-cci.ca/sites/default/files/CIC2014-AbstractsProgram.pdf [accessed 10.06.15].
16. Skowronski D.M., Chambers C., Sabaiduc S., De Serres G., Winter A.L., Dickinson J.A., et al. Integrated sentinel surveillance linking genetic, antigenic, and epidemiologic monitoring of influenza vaccine-virus relatedness and effectiveness during the 2013-2014 influenza season. J Infect Dis 2015, [Epub ahead of print].
17. Pebody R.G., Green H.K., Andrews N., Zhao H., Boddington N., Bawa Z., et al. Uptake and impact of a new live attenuated influenza vaccine programme in England: early results of a pilot in primary school-age children, 2013/14 influenza season. Euro Surveill 2014, 19:1-9.
18. ®, MedImmune, Gaithersburg, MD.
19. Cotter C.R., Jin H., Chen Z. A single amino acid in the stalk region of the H1N1pdm influenza virus HA protein affects viral fusion, stability and infectivity. PLoS Pathog 2014, 10:e1003831.
20. Barr I.G., Cui L., Komadina N., Lee R.T., Lin R.T., Deng Y., et al. A new pandemic influenza A(H1N1) genetic variant predominated in the winter 2010 influenza season in Australia, New Zealand and Singapore. Euro Surveill 2010, 15.